ArticleAlimentary pharmacology & therapeutics2020
Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease.
Article in Alimentary pharmacology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.Gut microbes · 2023Pooled it
- Faecal Metabolomics in Paediatric Inflammatory Bowel Disease: A Systematic Review.Journal of Crohn's & colitis · 2022Pooled it
- A Systematic Review of Artificial Intelligence and Machine Learning Applications to Inflammatory Bowel Disease, with Practical Guidelines for Interpretation.Inflammatory bowel diseases · 2022Pooled it
- Article
- Alterations of gut microbiota and metabolites in children with Crohn's disease and their correlation with disease activity.Translational pediatrics · 2025Article
- Multiomics-Based Profiling of the Fecal Microbiome Reveals Potential Disease-Specific Signatures in Pediatric IBD (PIBD).Biomolecules · 2025Article
- Consumption of only wild foods induces large scale, partially persistent alterations to the gut microbiome.Scientific reports · 2025Article
- Article
- Altered mucosal bacteria and metabolomics in patients with Peutz-Jeghers syndrome.Gut pathogens · 2024Article
- ExpLOring the role of the intestinal MiCrobiome in InflammATory bowel disease-AssocIated SpONdylarthritis (LOCATION-IBD).Heliyon · 2024Article
- A Comprehensive NMR Analysis of Serum and Fecal Metabolites in Familial Dysautonomia Patients Reveals Significant Metabolic Perturbations.Metabolites · 2023Article
- Big Data in Gastroenterology Research.International journal of molecular sciences · 2023Review
- Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment.Frontiers in immunology · 2023Review
- The gut microbiome in children with mood, anxiety, and neurodevelopmental disorders: An umbrella review.Gut microbiome (Cambridge, England) · 2023Review
- Repeated and multiple fecal microbiota transplantations plus partial enteral nutrition as the first-line treatment in active pediatric Crohn's disease.Frontiers in cellular and infection microbiology · 2023Article
- A novel clinical radiomics nomogram at baseline to predict mucosal healing in Crohn's disease patients treated with infliximab.European radiology · 2022Article
- Gut Microbial Metabolite-Mediated Regulation of the Intestinal Barrier in the Pathogenesis of Inflammatory Bowel Disease.Nutrients · 2021Review
- Metabolomics facilitate the personalized management in inflammatory bowel disease.Therapeutic advances in gastroenterology · 2021Review
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe gastrointestinal microbiota has an important role in mucosal immune homoeostasis and may contribute to maintaining mucosal healing in Crohn's disease (CD).
aimTo identify changes in the microbiota, metabolome and protease activity associated with mucosal healing in established paediatric CD
methodsTwenty-five participants aged 3-18 years with CD, disease duration of over 6 months, and maintenance treatment with biological therapy were recruited. They were divided into a low calprotectin group (faecal calprotectin <100 μg/g, "mucosal healing," n = 11), and a high calprotectin group (faecal calprotectin >100 μg/g, "mucosal inflammation," n = 11). 16S gene-based metataxonomics,
resultsRelative abundance of Dialister species was six-times greater in the low calprotectin group (q = 0.00999). Alpha and beta diversity, total protease activity and inferred metagenomic profiles did not differ between groups. Pentanoate (valerate) and lysine were principal discriminators in a machine-learning model which differentiated high and low calprotectin samples using NMR spectra (R
conclusionsThis multiomic study identified an increase in Dialister species and pentanoate, and a decrease in lysine, in patients with "mucosal healing." It supports further investigation of these as potential novel therapeutic targets in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.